The estimated Net Worth of James B Tananbaum is at least $26.1 million dollars as of 11 June 2007. James Tananbaum owns over 363,310 units of Cortexyme Inc stock worth over $381,714 and over the last 19 years James sold CRTX stock worth over $25,737,041.
James has made over 5 trades of the Cortexyme Inc stock since 2006, according to the Form 4 filled with the SEC. Most recently James sold 195,751 units of CRTX stock worth $448,270 on 14 June 2007.
The largest trade James's ever made was selling 1,102,167 units of Cortexyme Inc stock on 1 June 2007 worth over $3,064,024. On average, James trades about 121,060 units every 7 days since 2005. As of 11 June 2007 James still owns at least 195,751 units of Cortexyme Inc stock.
You can see the complete history of James Tananbaum stock trades at the bottom of the page.
James's mailing address filed with the SEC is 435 TASSO STREET, SUITE 200, PALO ALTO, CA, 94301.
Over the last 21 years, insiders at Cortexyme Inc have traded over $59,595,534 worth of Cortexyme Inc stock and bought 19,273,711 units worth $164,053,955 . The most active insiders traders include & Johnson Johnson & Johnson..., Farmaceutici Sp A Chiesi et Ansbert Gadicke. On average, Cortexyme Inc executives and independent directors trade stock every 59 days with the average trade being worth of $475,426. The most recent stock trade was executed by Caryn Gordon Mc Dowell on 6 June 2022, trading 10,800 units of CRTX stock currently worth $30,888.
Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Based upon the evidence generated to date, Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the GAIN Trial, an ongoing Phase 2/3 clinical trial in patients with mild to moderate Alzheimer's disease. Cortexyme is targeting a specific, infectious pathogen found in the brain and other organs and tied to degeneration and inflammation in humans and animal models.
Cortexyme Inc executives and other stock owners filed with the SEC include: